SEC Form 10-Q filed by CeriBell Inc.
$CBLL
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2025 | $19.00 | Strong Buy | Raymond James |
| 6/24/2025 | $30.00 | Buy | BTIG Research |
| 4/4/2025 | $32.00 | Buy | Ladenburg Thalmann |
| 11/5/2024 | $32.00 | Buy | BofA Securities |
| 11/5/2024 | $30.00 | Buy | Canaccord Genuity |
| 11/5/2024 | $32.00 | Overweight | JP Morgan |
| 11/5/2024 | $31.00 | Buy | TD Cowen |
| 11/5/2024 | Outperform | William Blair |
4 - Ceribell, Inc. (0001861107) (Issuer)
4 - Ceribell, Inc. (0001861107) (Issuer)
Raymond James initiated coverage of CeriBell with a rating of Strong Buy and set a new price target of $19.00
BTIG Research initiated coverage of CeriBell with a rating of Buy and set a new price target of $30.00
Ladenburg Thalmann initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00
SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 46th Annual Growth Stock Conference in Chicago. The presentation will take place on Wednesday, June 3, 2026, at 9:20 a.m. Pacific Daylight Time / 11:20 a.m. Central Daylight Time. Event: William Blair 46th Annual Growth Stock Conference Date: Wednesday, June 3, 2026Time: 9:20 a.m. PDT / 11:20 a.m. CDT A live and archived webcast of the presentation will be availabl
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 & Recent Highlights Reported total revenue of $26.5 million in the first quarter of 2026, a 29% increase compared to the same period in 2025Ended the quarter with 680 total active accountsAchieved gross margin of 87%Initiated commercial launch of neonate and pediatric products following successful pilotReceived supportive CMS proposed rule for NTAP reimbursement for del
SUNNYVALE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Bank of America Securities 2026 Health Care Conference. The fireside chat will take place on Wednesday, May 13, 2026, at 3:40 p.m. Pacific Standard Time / 6:40 p.m. Eastern Standard Time. Event: Bank of America Securities 2026 Health Care ConferenceDate: Wednesday, May 13, 2026Time: 3:40 p.m. PST / 6:40 p.m. EST A live and archi
8-K - Ceribell, Inc. (0001861107) (Filer)
10-Q - Ceribell, Inc. (0001861107) (Filer)
8-K - Ceribell, Inc. (0001861107) (Filer)
4 - Ceribell, Inc. (0001861107) (Issuer)
4 - Ceribell, Inc. (0001861107) (Issuer)
4 - Ceribell, Inc. (0001861107) (Issuer)
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 & Recent Highlights Reported total revenue of $26.5 million in the first quarter of 2026, a 29% increase compared to the same period in 2025Ended the quarter with 680 total active accountsAchieved gross margin of 87%Initiated commercial launch of neonate and pediatric products following successful pilotReceived supportive CMS proposed rule for NTAP reimbursement for del
SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Monday, May 11, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 11, 2026. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 1880547. A li
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 & Recent Highlights Reported total revenue of $24.8 million in the fourth quarter of 2025, a 34% increase compared to the same period in 2024Delivered total revenue of $89.1 million for the full year of 2025, a 36% increase over the prior yearEnded the year with 647 total active accountsAchieved gross margin of 87% in the fourth quarter of 2025 and 8
SC 13G - Ceribell, Inc. (0001861107) (Subject)
SC 13D - Ceribell, Inc. (0001861107) (Subject)
SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades of experience leading high-growth, innovative medical device companies to Ceribell's Board as the Company executes on its mission to expand patient access to timely brain monitoring in the acute care setting. Ms. Rogers is an accomplished healthcare executive with board experience in both the public and private sectors. She most recently
—Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions ("Ceribell"), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. "Ms. Rodenbush and Mr. Price bring an impressive wealth of experience to Ceribell, and I am confident that their leadership across our People & Culture and Marketing fu